Literature DB >> 31495687

Safe Cardioversion for Patients With Acute-Onset Atrial Fibrillation and Flutter: Practical Concerns and Considerations.

Ian G Stiell1, M Sean McMurtry2, Andrew McRae3, Ratika Parkash4, Frank Scheuermeyer5, Clare L Atzema6, Allan Skanes7.   

Abstract

In this Viewpoint concerns raised by Canadian emergency physicians regarding recommendations 2 and 6 from the recent Canadian Cardiovascular Society 2018 update for atrial fibrillation are discussed. These recommendations narrow the window for safe cardioversion and suggest 4 weeks of anticoagulation for all patients who undergo urgent cardioversion regardless of their CHADS-65 status. We discuss the implications of Grading of Recommendations, Assessment, Development, and Evaluation weak recommendations on the basis of low-quality evidence.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31495687     DOI: 10.1016/j.cjca.2019.06.007

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  4 in total

1.  Just the facts: atrial fibrillation or flutter in patients who are candidates for rhythm control.

Authors:  Ian G Stiell; Elisha Targonsky; Frank Scheuermeyer
Journal:  CJEM       Date:  2021-04-06       Impact factor: 2.410

2.  Which Recommendations Are You Using? A Survey of Emergency Physician Management of Paroxysmal Atrial Fibrillation.

Authors:  Ryan C Daniel; Clare L Atzema; Dennis D Cho; Philip J Davis; Lorne L Costello
Journal:  CJC Open       Date:  2022-01-23

3.  Management of paroxysmal atrial flutter that occurred in an outpatient prior to dental surgery: a case report.

Authors:  Hajime Shimoda; Tetsu Takahashi
Journal:  BMC Oral Health       Date:  2019-12-04       Impact factor: 2.757

Review 4.  2021 CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist.

Authors:  Ian G Stiell; Kerstin de Wit; Frank X Scheuermeyer; Alain Vadeboncoeur; Paul Angaran; Debra Eagles; Ian D Graham; Clare L Atzema; Patrick M Archambault; Troy Tebbenham; Andrew D McRae; Warren J Cheung; Ratika Parkash; Marc W Deyell; Geneviève Baril; Rick Mann; Rupinder Sahsi; Suneel Upadhye; Erica Brown; Jennifer Brinkhurst; Christian Chabot; Allan Skanes
Journal:  CJEM       Date:  2021-08-12       Impact factor: 2.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.